IN2014CH00378A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CH00378A IN2014CH00378A IN378CH2014A IN2014CH00378A IN 2014CH00378 A IN2014CH00378 A IN 2014CH00378A IN 378CH2014 A IN378CH2014 A IN 378CH2014A IN 2014CH00378 A IN2014CH00378 A IN 2014CH00378A
- Authority
- IN
- India
- Prior art keywords
- factor
- plasma
- levels
- impurity
- chromatography
- Prior art date
Links
- 239000012535 impurity Substances 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract 2
- 102000008100 Human Serum Albumin Human genes 0.000 abstract 2
- 108091006905 Human Serum Albumin Proteins 0.000 abstract 2
- 239000003114 blood coagulation factor Substances 0.000 abstract 2
- 238000004587 chromatography analysis Methods 0.000 abstract 2
- 229960004222 factor ix Drugs 0.000 abstract 2
- 238000000746 purification Methods 0.000 abstract 2
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 1
- 102100023804 Coagulation factor VII Human genes 0.000 abstract 1
- 108010076282 Factor IX Proteins 0.000 abstract 1
- 108010023321 Factor VII Proteins 0.000 abstract 1
- 108010014173 Factor X Proteins 0.000 abstract 1
- 108010071241 Factor XIIa Proteins 0.000 abstract 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 108010094028 Prothrombin Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
- 229910052782 aluminium Inorganic materials 0.000 abstract 1
- 239000004411 aluminium Substances 0.000 abstract 1
- 230000003171 anti-complementary effect Effects 0.000 abstract 1
- 238000011210 chromatographic step Methods 0.000 abstract 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 238000009826 distribution Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000012869 ethanol precipitation Methods 0.000 abstract 1
- 229940012413 factor vii Drugs 0.000 abstract 1
- 229960000301 factor viii Drugs 0.000 abstract 1
- 238000005194 fractionation Methods 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/10—Process efficiency
Landscapes
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/530,840 US9663553B2 (en) | 2014-01-29 | 2014-11-03 | Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma |
| IN378CH2014 IN2014CH00378A (https=) | 2014-01-29 | 2015-01-28 | |
| PCT/IN2015/000055 WO2015114664A1 (en) | 2014-01-29 | 2015-01-28 | An integrated process for the production of therapeutics (human albumin, intravenous immunoglobulins, clotting factor viii and clotting factor ix) from human plasma |
| EP15717662.9A EP3099702A1 (en) | 2014-01-29 | 2015-01-28 | An integrated process for the production of therapeutics (human albumin, intravenous immunoglobulins, clotting factor viii and clotting factor ix) from human plasma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN378CH2014 IN2014CH00378A (https=) | 2014-01-29 | 2015-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CH00378A true IN2014CH00378A (https=) | 2015-08-07 |
Family
ID=52991912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN378CH2014 IN2014CH00378A (https=) | 2014-01-29 | 2015-01-28 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9663553B2 (https=) |
| EP (1) | EP3099702A1 (https=) |
| IN (1) | IN2014CH00378A (https=) |
| WO (1) | WO2015114664A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111991571A (zh) * | 2020-08-12 | 2020-11-27 | 湖州师范学院 | 一种柱上低pH病毒灭活的方法 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9932388B2 (en) * | 2014-11-13 | 2018-04-03 | Hemarus Therapeutics Limited | Chromatographic process for producing high purity fibrinogen and thrombin |
| US9556253B2 (en) * | 2014-12-02 | 2017-01-31 | Hemarus Therapeutics Limited | Process for increased yield of immunoglobulin from human plasma |
| EP3638693A4 (en) * | 2017-06-12 | 2021-04-14 | Kamada Ltd | IMMUNOGLOBULIN COMPOSITIONS AND PROCESS FOR THEIR PREPARATION |
| CN108733099B (zh) * | 2018-05-31 | 2020-08-11 | 上海药明生物技术有限公司 | 低pH孵育和中和的自动调节系统及方法 |
| CN111499736B (zh) * | 2020-04-28 | 2021-04-30 | 国药集团武汉血液制品有限公司 | 一种静注covid-19人免疫球蛋白的制备方法 |
| EP3945095A1 (en) * | 2020-07-28 | 2022-02-02 | Bia Separations D.O.O. | A process for the purification of prothrombin complex concentrate (pcc) and fix from complete plasma or cryo-poor plasma |
| CN112574296B (zh) * | 2020-12-30 | 2023-05-19 | 中国医学科学院输血研究所 | 一种模拟IVIg的多人份混合人血浆IgG样品的分离纯化方法 |
| CN113831405B (zh) * | 2021-11-17 | 2024-04-30 | 华兰生物工程重庆有限公司 | 一种人血白蛋白的纯化方法 |
| CN116236820A (zh) * | 2023-03-24 | 2023-06-09 | 华兰生物工程重庆有限公司 | 一种单人份血浆IgG制品的连续生产系统 |
| CN116217710B (zh) * | 2023-04-23 | 2025-05-27 | 华兰生物工程重庆有限公司 | 一种从血浆中提取分离IgM与凝血因子Ⅶ的方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2390074A (en) | 1942-02-09 | 1945-12-04 | Research Corp | Protein product and process |
| JPS5128727A (https=) | 1974-09-04 | 1976-03-11 | Canon Kk | |
| JPS52125609A (en) | 1976-04-09 | 1977-10-21 | Green Cross Corp:The | Purification of agglutination factor viii |
| US4228154A (en) | 1979-02-26 | 1980-10-14 | Armour Pharmaceutical Company | Purification of plasma albumin by ion exchange chromatography |
| US4371520A (en) | 1981-10-28 | 1983-02-01 | The Green Cross Corporation | Process for preparing immunoglobulin suitable for intravenous injection |
| US4639513A (en) | 1984-02-02 | 1987-01-27 | Cuno Inc. | Intravenously injectable immunoglobulin G (IGG) and method for producing same |
| US5614500A (en) | 1983-03-04 | 1997-03-25 | The Scripps Research Institute | Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography |
| FR2543448A1 (fr) | 1983-04-01 | 1984-10-05 | Rhone Poulenc Spec Chim | Procede de fractionnement du plasma |
| US6258938B1 (en) | 1983-10-28 | 2001-07-10 | Ne Medical Center Hospital, Inc. | Method for the purification and isolation of blood clotting proteins using conformation specific antibodies |
| JPS63108000A (ja) | 1986-05-15 | 1988-05-12 | Green Cross Corp:The | 第８因子の精製方法 |
| DE3640513A1 (de) | 1986-11-27 | 1988-06-09 | Biotest Pharma Gmbh | Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates |
| DE3877529T2 (de) | 1987-10-23 | 1996-11-07 | Centre Regional De Transfusion | Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat und dessen therapeutische Verwendung. |
| DE3914869C1 (https=) | 1989-05-05 | 1990-08-09 | Biotest Pharma Gmbh, 6072 Dreieich, De | |
| US5138034A (en) | 1989-07-12 | 1992-08-11 | The Green Cross Corporation | Method of fractionating plasma proteins |
| FR2651437A1 (fr) | 1989-09-05 | 1991-03-08 | Lille Transfusion Sanguine | Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total. |
| DK162233C (da) * | 1989-11-09 | 1992-03-16 | Novo Nordisk As | Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii |
| FR2672604B1 (fr) * | 1991-02-07 | 1995-05-05 | Pasteur Merieux Serums Vacc | Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue. |
| ATE195877T1 (de) | 1991-03-01 | 2000-09-15 | Rhone Poulenc Rorer Int | Herstellung von faktor-ix |
| IT1262899B (it) | 1992-03-27 | 1996-07-22 | Sclavo Spa | Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano |
| FR2690444B1 (fr) | 1992-04-22 | 1995-07-13 | Rucheton Marcel | Procede de preparation d'une solution d'albumine plasmatique purifiee. |
| US5286849A (en) | 1992-07-14 | 1994-02-15 | Alpha Therapeutic Corporation | Purification of factor IX |
| FR2706466B1 (fr) | 1993-06-14 | 1995-08-25 | Aetsrn | Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré. |
| US5714583A (en) * | 1995-06-07 | 1998-02-03 | Genetics Institute, Inc. | Factor IX purification methods |
| US5659017A (en) * | 1995-11-07 | 1997-08-19 | Alpha Therapeutic Corporation | Anion exchange process for the purification of Factor VIII |
| TW491855B (en) | 1996-08-07 | 2002-06-21 | Csl Ltd | Purification of immunoglobulins |
| DK2270044T3 (en) | 1998-06-09 | 2015-01-26 | Csl Behring Ag | Liquid immunoglobulin G (IgG) product |
| DE19932782A1 (de) | 1999-07-14 | 2001-01-18 | Biotest Pharma Gmbh | Verfahren zur chromatographischen Fraktionierung von Plasma oder Serum, so erhaltene Präparate und deren Verwendung |
| US6893639B2 (en) | 2001-10-19 | 2005-05-17 | Hemacare Corporation | Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates |
| US20040106779A1 (en) | 2002-12-03 | 2004-06-03 | Bigler Douglas E. | Modified factor IX preparation |
| EP3127916A1 (en) * | 2004-06-07 | 2017-02-08 | Therapure Biopharma Inc. | Isolation of plasma or serum proteins |
| MX2007002085A (es) | 2004-08-20 | 2007-07-19 | Prometic Biosciences Ltd | Esquemas de aislamiento y purificacion consecutivos de proteinas mediante cromatografia de afinidad. |
| US20070049732A1 (en) | 2005-09-01 | 2007-03-01 | Zurlo Eugene J | Ultra-high yield intravenous immune globulin preparation |
| WO2007063129A2 (en) | 2005-12-02 | 2007-06-07 | Novozymes A/S | Insolation of peptides , polypeptides and proteins |
| WO2007136327A1 (en) | 2006-05-22 | 2007-11-29 | Ge Healthcare Bio-Sciences Ab | A method of producing igg |
| ES2294976B1 (es) | 2007-11-12 | 2008-12-16 | Grifols, S.A. | "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion". |
-
2014
- 2014-11-03 US US14/530,840 patent/US9663553B2/en active Active
-
2015
- 2015-01-28 EP EP15717662.9A patent/EP3099702A1/en not_active Withdrawn
- 2015-01-28 WO PCT/IN2015/000055 patent/WO2015114664A1/en not_active Ceased
- 2015-01-28 IN IN378CH2014 patent/IN2014CH00378A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111991571A (zh) * | 2020-08-12 | 2020-11-27 | 湖州师范学院 | 一种柱上低pH病毒灭活的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20150210737A1 (en) | 2015-07-30 |
| WO2015114664A1 (en) | 2015-08-06 |
| US9663553B2 (en) | 2017-05-30 |
| EP3099702A1 (en) | 2016-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CH00378A (https=) | ||
| ES2813398T3 (es) | Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A | |
| JP2022116038A (ja) | 二重特異性抗体を製造する方法、二重特異性抗体及びこのような抗体の治療的使用 | |
| RU2018106364A (ru) | Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств | |
| AR097651A1 (es) | Métodos y composiciones que comprenden polipéptidos recombinantes purificados | |
| EA201491564A1 (ru) | Осаждение фракции i-iv-1 иммуноглобулинов из плазмы | |
| MX2013006611A (es) | Tratamiento de formaciones iliticas al usar un agente quelante. | |
| HRP20161740T1 (hr) | Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b | |
| EP3308798A3 (en) | Polypeptides and antibodies for treating hbv infection and related diseases | |
| CA2926301A1 (en) | Low acidic species compositions and methods for producing and using the same | |
| PH12022550505A1 (en) | Compositions and methods for the treatment of viral infections | |
| JP2016538876A5 (https=) | ||
| MX2016001601A (es) | Separacion de anticuerpos biespecificos y subproductos de produccion de anticuerpos biespecificos utilizando cromatografia de hidroxiapatita. | |
| EP3261720A1 (en) | Antibodies to tau and uses thereof | |
| GB2496337A (en) | Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases | |
| MX2023006291A (es) | Metodos para purificar proteinas que contienen fc. | |
| Prasad et al. | Intravenous immunoglobulin in pediatrics: A review | |
| TWI610937B (zh) | 用於降低血漿來源免疫球蛋白組成物之血栓性栓塞可能性的方法 | |
| HRP20220197T1 (hr) | Antitijela protiv il-22r | |
| EA201990593A1 (ru) | Непрерывный способ для снижения гетерогенности терапевтического белка | |
| EA201691834A1 (ru) | Новый способ очистки гонадотропина | |
| JP2017507132A (ja) | 抗体プロセス | |
| Weng et al. | Anti-human platelet antigen-1a immunoglobulin G preparation intended to prevent fetal and neonatal alloimmune thrombocytopenia | |
| UA85741C2 (ru) | Способ получения иммуноглобулина | |
| Fujimoto et al. | Establishment of a monoclonal antibody against cd81 that decreases the proliferation of rat glioma cells |